Loading...
Market
Will PBGENE-HBV trial expand to other countries by mid-2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Announcements from Precision BioSciences or regulatory approvals in new countries
Story
Moldova Approves Precision BioSciences' PBGENE-HBV Gene Editing Study for Chronic Hepatitis B
Oct 24, 2024, 12:51 PM
Moldova has approved its first gene editing study for human trials targeting Hepatitis B virus (HBV). Precision BioSciences has received the necessary approval to initiate the PBGENE-HBV clinical trial, which aims to test the effectiveness of gene editing in removing persistent viral DNA in patients with chronic HBV. This marks a significant step in gene therapy, as it will be the first human trial using such technology to address this viral infection.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Yes • 50%
No • 50%
Fewer than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%
More than 30 countries • 25%
USA • 25%
UK • 25%
South Africa • 25%
Other • 25%
<10 countries • 25%
10-20 countries • 25%
20-30 countries • 25%
>30 countries • 25%
